Novartis eyes Prague centre expansion

…benefits of treatment rather than prices of drugs, which are one of the lowest in Europe. Novartis saw its turnover in the Czech Republic reaching CZK 5.7bn (€218m) in 2016, up by around 6% year on year. In 2017, the company expects its turnover to grow by around 3%, the executive said.

Sign up now to open the entire news item.

You are allowed to open only one news item from PMR websites.
  • 1E-mail
    (to send requested information)
  • 2Brief profile
    (required for new e-mails only)

 required fields

You must accept PMR’s Privacy Policy.